GSK isn't revealing the size of the OS improvement yet – it has promised to do so at the American Society for Haematology ... At this year's ASCO cancer congress in February, earlier results ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Antibody-drug conjugates (ADCs) took centre stage at the European Society of Medical ... $1.5 billion from GSK, which licensed in an early stage ovarian and endometrial cancer drug, HS-20089 ...

Pharmaceutical giant GSK has inked a deal with the University of Oxford that will see it pump tens of millions of pounds into research for cancer vaccines. The FTSE 100 firm said under a ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says.

BIOTRONIK Neuro will unveil new data from the BENEFIT-03 clinical study at the North American Neuromodulation Society (NANS) 2025 Annual Meeting. The findings highlight the transformative potential of ...

Resbiotic Nutrition Inc. ("resbiotic" or "res"), a leading provider of physician-formulated and science-backed dietary supplements, has announced a strategic distribution agreement with Grupo Columbia ...

Public-health officials, activists, tech executives and others press everyday Americans to let “experts” and “authorities” control decisions that affect all of society. Technology allows ...